Carvacrol and trans-cinnamaldehyde reduce Clostridium difficile toxin production and cytotoxicity in vitro

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 4415-4430

  Mooyottu, Shankumar ^a   Kollanoor Johny, Anup ^a   Flock, Genevieve ^a   Bouillaut, Laurent ^b   Upadhyay, Abhinav ^a   Sonenshein, Abraham L ^b   Venkitanarayanan, Kumar ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Gene expression; Plant compounds; Toxins

Indexed keywords

BACTERIAL TOXIN; CARVACROL; CINNAMALDEHYDE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; ACROLEIN; BACTERIAL PROTEIN; TERPENE;

ANIMAL CELL; ARTICLE; BACTERIAL GENE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; REAL TIME POLYMERASE CHAIN REACTION; SUB INHIBITORY CONCENTRATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PEPTOCLOSTRIDIUM DIFFICILE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACROLEIN; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MONOTERPENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84896473782     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15034415     Document Type: Article

References (50)

1. Bartlett, J. G. Clostridium difficile infection: Pathophysiology and diagnosis. Semin. Gastrointest. Dis. 1997, 8, 12-21.
2. Weese, J. S. Clostridium difficile in food-Innocent bystander or serious threat? Clin. Microbiol. Infect. 2010, 16, 3-10.
3. Ghose, C.; Kalsy, A.; Sheikh, A.; Rollenhagen, J.; John, M.; Young, J.; Rollins, S. M.; Qadri, F.; Calderwood, S. B.; Kelly, C. P.; et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin a-neutralizing antibodies in mice. Infect. Immun. 2007, 75, 2826-2832.
4. Wilkins, T. D.; Lyerly, D. M. Clostridium difficile testing: After 20 years, still challenging. J. Clin. Microbiol. 2003, 41, 531-534.
5. Blossom, D. B.; McDonald, L. C. The challenges posed by reemerging Clostridium difficile infection. Clin. Infect. Dis. 2007, 45, 222-227.
6. Hookman, P.; Barkin, J. S. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 2009, 15, 1554-1580.
7. Sunenshine, R. H.; McDonald, L. C. Clostridium difficile-associated disease: New challenges from an established pathogen. Clevel. Clin. J. Med. 2006, 73, 187-197.
8. Dial, S.; Delaney, J. A.; Barkun, A. N.; Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294, 2989-2995.
9. Keel, M. K.; Songer, J. G. The comparative pathology of Clostridium difficile-associated disease. Vet. Pathol. 2006, 43, 225-240.
10. Von Eichel-Streiber, C.; Zec-Pirnat, I.; Grabnar, M.; Rupnik, M. A nonsense mutation abrogates production of a functional enterotoxin A in Clostridium difficile toxinotype VIII strains of serogroups F and X. FEMS Microbiol. Lett. 1999, 178, 163-168.
11. McDonald, L. C.; Owings, M.; Jernigan, D. B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 2006, 12, 409-415.
12. Antunes, A.; Martin-Verstraete, I.; Dupuy, B. CcpA-mediated repression of Clostridium difficile toxin gene expression. Mol. Microbiol. 2011, 79, 882-899.
13. Antunes, A.; Camiade, E.; Monot, M.; Courtois, E.; Barbut, F.; Sernova, N. V.; Rodionov, D. A.; Martin-Verstraete, I.; Dupuy, B. Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile. Nucleic Acids Res. 2012, 40, 10701-10718.
14. Dineen, S. S.; McBride, S. M.; Sonenshein, A. L. Integration of metabolism and virulence by Clostridium difficile CodY. J. Bacteriol. 2010, 192, 5350-5362.
15. Dineen, S. S.; Villapakkam, A. C.; Nordman, J. T.; Sonenshein, A. L. Repression of Clostridium difficile toxin gene expression by CodY. Mol. Microbiol. 2007, 66, 206-219.
16. Bartlett, J. G. Antibiotic-associated diarrhea. Clin. Infect. Dis. 1992, 15, 573-581.
17. O'Connor, K. A.; Kingston, M.; O'Donovan, M.; Cryan, B.; Twomey, C.; O'Mahony, D. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM 2004, 97, 423-429.
18. Prabaker, K.; Weinstein, R. A. Trends in antimicrobial resistance in intensive care units in the United States. Curr. Opin. Crit. Care 2011, 17, 472-479.
19. Spigaglia, P.; Barbanti, F.; Mastrantonio, P. European study group on Clostridium difficile (ESGCD). Multidrug resistance in European Clostridium difficile clinical isolates. J. Antimicrob. Chemother. 2011, 66, 2227-2234.
20. Johny, A. K.; Hoagland, T.; Venkitanarayanan, K. Effect of Subinhibitory concentrations of plant-derived molecules in increasing the sensitivity of multidrug-resistant salmonella enterica serovar typhimurium DT104 to antibiotics. Foodborne Pathog. Dis. 2010, 7, 1165-1170.
21. Baser, K. H. Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr. Pharm. Des. 2008, 14, 3106-3119.
22. Amalaradjou, M. A.; Narayanan, A.; Venkitanarayanan, K. Trans-cinnamaldehyde decreases attachment and invasion of uropathogenic escherichia coli in urinary tract epithelial cells by modulating virulence gene expression. J. Urol. 2011, 185, 1526-1531.
23. Amalaradjou, M. A.; Narayanan, A.; Baskaran, S. A.; Venkitanarayanan, K. Antibiofilm effect of trans-cinnamaldehyde on uropathogenic Escherichia coli. J. Urol. 2010, 184, 358-363.
24. Merrigan, M.; Venugopal, A.; Mallozzi, M.; Roxas, B.; Viswanathan, V. K.; Johnson, S.; Gerding, D. N.; Vedantam, G. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J. Bacteriol. 2010, 192, 4904-4911.
25. Baines, S. D.; Freeman, J.; Wilcox, M. H. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J. Antimicrob. Chemother. 2005, 55, 974-982.
26. He, D.; Sougioultzis, S.; Hagen, S.; Liu, J.; Keates, S.; Keates, A. C.; Pothoulakis, C.; Lamont, J. T. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 2002, 122, 1048-1057.
27. Feltis, B. A.; Wiesner, S. M.; Kim, A. S.; Erlandsen, S. L.; Lyerly, D. L.; Wilkins, T. D.; Wells, C. L. Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock 2000, 14, 629-634.
28. Castagliuolo, I.; Keates, A. C.; Wang, C. C.; Pasha, A.; Valenick, L.; Kelly, C. P.; Nikulasson, S. T.; LaMont, J. T.; Pothoulakis, C. Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J. Immunol. 1998, 160, 6039-6045.
29. Kelly, C. P.; Becker, S.; Linevsky, J. K.; Joshi, M. A.; O'Keane, J. C.; Dickey, B. F.; LaMont, J. T.; Pothoulakis, C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Investig. 1994, 93, 1257-1265.
30. Rasko, D. A.; Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 2010, 9, 117-128.
31. Cegelski, L.; Marshall, G. R.; Eldridge, G. R.; Hultgren, S. J. The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 2008, 6, 17-27.
32. Hung, D. T.; Shakhnovich, E. A.; Pierson, E.; Mekalanos, J. J. Small-molecule inhibitor of vibrio cholerae virulence and intestinal colonization. Science 2005, 310, 670-674.
33. Hughes, D. T.; Sperandio, V. Inter-Kingdom signalling: Communication between bacteria and their hosts. Nat. Rev. Microbiol. 2008, 6, 111-120.
34. Tsui, W. H.; Yim, G.; Wang, H. H.; McClure, J. E.; Surette, M. G.; Davies, J. Dual effects of MLS antibiotics: Transcriptional modulation and interactions on the ribosome. Chem. Biol. 2004, 11, 1307-1316.
35. Rupa, P.; Mine, Y. Recent advances in the role of probiotics in human inflammation and gut health. J. Agric. Food Chem. 2012, 60, 8249-8256.
36. Jamroz, D.; Wiliczkiewicz, A.; Wertelecki, T.; Orda, J.; Skorupinska, J. Use of active substances of plant origin in chicken diets based on maize and locally grown cereals. Br. Poult. Sci. 2005, 46, 485-493.
37. Si, W.; Gong, J.; Chanas, C.; Cui, S.; Yu, H.; Caballero, C.; Friendship, R. M. In Vitro assessment of antimicrobial activity of carvacrol, thymol and cinnamaldehyde towards salmonella serotype typhimurium DT104: Effects of pig diets and emulsification in hydrocolloids. J. Appl. Microbiol. 2006, 101, 1282-1291.
38. Ultee, A.; Smid, E. J. Influence of carvacrol on growth and toxin production by bacillus cereus. Int. J. Food Microbiol. 2001, 64, 373-378.
39. Upadhyay, A.; Johny, A. K.; Amalaradjou, M. A.; Ananda Baskaran, S.; Kim, K. S.; Venkitanarayanan, K. Plant-derived antimicrobials reduce listeria monocytogenes virulence factors in vitro, and down-regulate expression of virulence genes. Int. J. Food Microbiol. 2012, 157, 88-94.
40. Mani, N.; Lyras, D.; Barroso, L.; Howarth, P.; Wilkins, T.; Rood, J. I.; Sonenshein, A. L.; Dupuy, B. Environmental response and autoregulation of Clostridium difficile TxeR, a sigma factor for toxin gene expression. J. Bacteriol. 2002, 184, 5971-5978.
41. Guedon, E.; Serror, P.; Ehrlich, S. D.; Renault, P.; Delorme, C. Pleiotropic transcriptional repressor CodY senses the intracellular pool of branched-chain amino acids in lactococcus lactis. Mol. Microbiol. 2001, 40, 1227-1239.
42. Pohl, K.; Francois, P.; Stenz, L.; Schlink, F.; Geiger, T.; Herbert, S.; Goerke, C.; Schrenzel, J.; Wolz, C. CodY in staphylococcus aureus: A regulatory link between metabolism and virulence gene expression. J. Bacteriol. 2009, 191, 2953-2963.
43. Stenz, L.; Francois, P.; Whiteson, K.; Wolz, C.; Linder, P.; Schrenzel, J. The CodY pleiotropic repressor controls virulence in gram-positive pathogens. FEMS Immunol. Med. Microbiol. 2011, 62, 123-139.
44. Rivera, F. E.; Miller, H. K.; Kolar, S. L.; Stevens, S. M., Jr.; Shaw, L. N. The impact of CodY on virulence determinant production in community-associated methicillin-resistant staphylococcus aureus. Proteomics 2012, 12, 263-268.
45. Montgomery, C. P.; Boyle-Vavra, S.; Roux, A.; Ebine, K.; Sonenshein, A. L.; Daum, R. S. CodY deletion enhances in vivo virulence of community-associated methicillin-resistant staphylococcus aureus clone USA300. Infect. Immun. 2012, 80, 2382-2389.
46. Vohra, P.; Poxton, I. R. Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiology 2011, 157, 1343-1353.
47. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods 2001, 25, 402-408.
48. Francis, M. B.; Allen, C. A.; Shrestha, R.; Sorg, J. A. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 2013, 9, e1003356.
49. Bouillaut, L.; Self, W. T.; Sonenshein, A. L. Proline-dependent regulation of Clostridium difficile stickland metabolism. J. Bacteriol. 2013, 195, 844-854.
50. Carter, G. P.; Douce, G. R.; Govind, R.; Howarth, P. M.; Mackin, K. E.; Spencer, J.; Buckley, A. M.; Antunes, A.; Kotsanas, D.; Jenkin, G. A.; et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 2011, 7, e1002317.